Resonant uses its IMPaCT tumor microenvironment models and data platform to discover targets and functionally active anti-tumor antibodies to treat more difficult tumors. Through the agreement, Retrogenix will perform targeted screening to discover antibodies in Resonant’s collection to find therapeutic candidates for targeting tumors.
“We look forward to working with Resonant to deconvolute the targets for their antibodies,” co-managing director of Retrogenix Jo Soden said in a news release. “Resonant’s innovative platform is delivering functional therapeutic candidates at a rapid pace and we welcome the opportunity to identify the specific, biologically relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”
According to the company, targets in the tumor microenvironment can include plasma membrane proteins and proteins that are typically secreted into the extracellular space. Retrogenix’s human proteins library can assess candidate antibodies for target binding.
“Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates. Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retogenix to enhance our growing pipeline of antibody candidates,” CEO of Resonant John Westwick said.